...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Urology >Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
【24h】

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge

机译：Pembrolizumab患者患者膀胱癌的患者的膀胱癌患者的膀胱癌的第一挑战症的成功反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We report a patient with advanced bladder cancer in which the primary lesion and metastatic site disappeared following the pembrolizumab therapy rechallenge after radiotherapy for bladder cancer lesion of nonresponse of pembrolizumab first challenge. A 76-year-old man with advanced bladder cancer received three courses of the chemotherapy with gemcitabine and cisplatin combination; however, the chemotherapy was stopped because of adverse events. The patient started pembrolizumab therapy; however, the effect was not observed. Radiation therapy was given to the primary lesion and pelvic lymph node metastases for the purpose of local control of the lesions. Because the primary lesion was regrowth and para-aortic lymph node metastasis appeared, pembrolizumab therapy was resumed. Thereafter, the primary lesion and metastatic site disappeared.
机译：我们向患有先进的膀胱癌报告患者，其中彭洛丽普疗法在放射治疗后膀胱癌损伤后的彭洛洛齐妥灭绝的攻击性第一挑战症的放射治疗后，原发性病变和转移性位点消失。 一个76岁的男子，晚期膀胱癌接受了吉西他滨和顺铂组合的三种化疗; 然而，由于不良事件，化疗被停止。 患者开始彭布罗齐松治疗; 但是，没有观察到效果。 为了局部控制病变，给予初级病变和盆腔淋巴结转移的放射治疗。 因为初级病变是再生和对主动脉淋巴结转移，因此恢复了Pembrolizumab疗法。 此后，主要病变和转移性位点消失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号